Drug-induced alopecia areata: A systematic review

Ezemma, Ogechi; Devjani, Shivali; Jothishankar, Balaji; Kelley, Kristen J.; Senna, Maryanne M.

doi:10.1016/j.jaad.2023.05.022

Journal of the American Academy of Dermatology

2024

DOI: 10.1016/j.jaad.2023.05.022

|View full text |Cite

Drug-induced alopecia areata: A systematic review

Ogechi Ezemma

Shivali Devjani

Balaji Jothishankar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 , 2 AA is more common in psoriasis patients and may rarely be triggered by biologics used to treat psoriasis (particularly TNF-α inhibitors). 3 However, in drug-induced AA cases, spontaneous hair regrowth is common upon drug discontinuation. 3 We report a case of treatment-resistant AU arising in a psoriasis patient in whom biologic discontinuation did not result in hair regrowth, but a switch to deucravacitinib led to a rapid improvement of AU.…”

mentioning

confidence: 99%

“… 3 However, in drug-induced AA cases, spontaneous hair regrowth is common upon drug discontinuation. 3 We report a case of treatment-resistant AU arising in a psoriasis patient in whom biologic discontinuation did not result in hair regrowth, but a switch to deucravacitinib led to a rapid improvement of AU. This is the first case reporting successful use of deucravacitinib in AA.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report

Oliel,

Moussa,

Stanciu

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Alopecia universalis is a severe, difficult to treat variant of alopecia areata that results in loss of hair on the scalp, eyebrows, eyelashes, and extremities. Deucravacitinib, a selective TYK2 inhibitor, has been recently approved in Canada, opening the door to novel uses of the drug. We present the case of a patient known for psoriasis who developed alopecia universalis resistant to many interventions (topical minoxidil and topical, intralesional, and systemic corticosteroids). We report the first case of successful rapid hair regrowth after starting deucravacitinib, which should prompt further inquiry into the use of TYK2 inhibitors in the management of alopecia areata.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report

Oliel,

Moussa,

Stanciu

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment

Wang,

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Cyclosporine is a potent immunosuppressive drug for various immune-mediated diseases in children. Cyclosporine’s expected therapeutic effect also carries a wide range of side effects. One of the most common and intriguing dermatological side effects is hypertrichosis. However, recent reports have recognized alopecia as a potential adverse effect of cyclosporine. Here, we report a case of a 29-month-old boy diagnosed with aplastic anemia. During cyclosporine therapy, the patient presented with hair loss on the scalp, which and subsequently spread to the eyebrows and eyelashes. The alopecic symptoms were not relieved following topical minoxidil liniment interventions. When the cyclosporine was discontinued, a remarkable improvement was observed in the scalp, with complete hair regrowth. Data concerning cyclosporine from the FDA Adverse Event Reporting System (FAERS) database were extracted from January 2004 to January 2023. Within FAERS, our post-marketing pharmacovigilance analysis detected the reporting association of cyclosporine and alopecia. In monotherapy, cyclosporine-induced alopecia was observed in 118 cases, and tacrolimus-induced alopecia signals were detected in 197 cases. Although the potential mechanism of medication-induced hair loss is unclear, we identified a potential correlation between alopecia and cyclosporine, and it is still necessary to adequately recognize and clinically monitor this paradoxical reaction.

show abstract

Drug-Induced Alopecia Areata From Upadacitinib

Chang,

Brownstone,

Hsu

2024

Cureus

View full text Add to dashboard Cite

This case report describes an unexpected occurrence of alopecia areata (AA) in a 55-year-old woman undergoing treatment with upadacitinib for atopic dermatitis. This patient developed AA approximately one year into her upadacitinib treatment for atopic dermatitis. This case highlights possible upadacitinib-induced AA, which has not been reported in the literature. Not only does this case demonstrate the typical timeline for drug-induced alopecia, but it also raises questions about whether upadacitinib can cause drug-induced alopecia.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Drug-induced alopecia areata: A systematic review

Cited by 3 publications

References 4 publications

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report

Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report

Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment

Drug-Induced Alopecia Areata From Upadacitinib

Contact Info

Product

Resources

About